Invivyd, Inc. (IVVD) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to InVivid's first quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. To remove yourself from the queue, you may press star 1-1 again. I would now like to hand the call over to Katie Fazzoni, SVP Finance. Please go ahead. Thank you, Operator. A short while ago, we issued a press release announcing our Q1 2025 financial results and business highlights. That press release and the slides that are being used on today's webcast can be found in the investor section of the InVivid website under the press release and events and presentation sections respectively. Today's discussion will be led by Mark Olia, Chairman of InVivid's Board of Directors. He is joined by Tim Lee, Chief Commercial Officer, Bill Duke, Chief Financial Officer, Dr. Robert Allen, Chief Scientific Officer, and Dr. Mark Wingertzahn, Senior Vice President of Clinical Development. During today's discussion, we will be making forward-looking statements concerning, among other things, our corporate and commercial strategy, our research and development activities, our regulatory plans, certain financial expectations, our future prospects, and other statements that are not historical facts. These forward-looking statements are covered within the meaning of the Private Securities Litigation Reform Act and are subject to various risks, assumptions, and uncertainties that may change over time and cause our actual results to differ materially from those expressed or implied today. These forward-looking statements speak only as of the date of this call and InVivid assume...